September 15, 2015
After 30 years, Gerald Nepom, MD, will leave his post as director of Benaroya Research Institute (BRI) Virginia Mason in Seattle. Dr. Nepom is credited with leading the institute in international prominence through research into rheumatoid arthritis, diabetes, multiple sclerosis, allergies and other immune-system disorders. “[A]n amazing 30-year history with major scientific and medical impacts,” says Kristi Pangrazio, Board of Directors chair.
He will continue with his own research, which focuses “on identifying and understanding molecular and genetic mechanisms contributing to pathogenesis of autoimmune disorders and using this information to evaluate autoreactive T cell lineage and fate determination.”
Dr. Nepom will also continue his 10-year tenure as director of the Immune Tolerance Network (ITN). In 2014, BRI was awarded $27 million annually for seven years to provide management and oversight of ITN’s research of the immune system diseases—one of the largest grants the National Institutes of Health has ever given.
As much as he characterizes his being director of BRI as “an exciting and fulfilling experience,” Dr. Nepom feels it is time to pass the baton. He says the research requires looking forward at least five years into the future. He told the BRI Board of Directors he thought “the institute deserved someone invested in the long-term strategic plan, and ITN deserves a focused effort.”
Jane Buckner, MD, is currently the associate director and will assume the title of president of BRI (with duties that are similar to Dr. Nepom’s) at the end of 2015.